Diese Webseite verwendet Cookies

Diese Seite verwendet Cookies, um Ihnen dieses Angebot leicht zugänglich zu machen, Inhalte zu personalisieren, Ihre Zugriffe auf die Webseite zu analysieren und Ihnen ggf. personalisierte Angebote unterbreiten zu können. Hierzu kann es notwendig sein, dass die Informationen über Ihre Verwendung der Webseite an Partner weitergegeben werden. Diese führen die gesammelten Informationen möglicherweise mit weiteren Daten zusammen, die Sie an anderer Stelle bereitgestellt haben. Eine Weitergabe erfolgt dabei aber nur mit Ihrer Einwilligung und unter Beachtung der datenschutzrechtlichen Vorgaben. Weiterführende Informationen über die hier verwendeten Cookies erfahren Sie in den folgenden Erklärungen zu den jeweiligen Cookies.

Notwendige Cookies helfen dabei, Ihnen die Funktionen der Webseite zugängig zu machen, indem sie Grundfunktionen die zuletzt angesehen Wertpapiere und Ihre Entscheidung für oder gegen die Nutzung der jeweiligen Cookies speichert. Die Webseite wird ohne diese Cookies nicht so funktionieren, wie es geplant ist.

Name Anbieter Zweck Ablauf Typ Verantwortlicher
CookieConsent3464 Moneyspecial Um diese Cookiebar auszublenden. 1 Jahr http Infront Financial Technology GmbH
Die Cookie-Erklärung wurde das letzte Mal am 21.08.2020 von Infront Financial Technology GmbH aktualisiert.
Drucken


Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Allschwil, Switzerland - May 23, 2024
Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2023, will be held on Thursday, June 13, 2024, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland.

Notes to Shareholders
The invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) today and will be distributed to Shareholders by post. It is also available, together with the company's Annual Report, consisting of the Business Report, Governance Report, Compensation Report, Financial Report, and for the first time, Sustainability Report, at www.idorsia.com/agm.

In order to attend and vote at the AGM, shareholders must be registered in the company's shareholder register by June 4, 2024, 17:00 CEST, at the latest.

Notes to the editor

Agenda for the AGM 2024

1.   Annual reporting 2023
1.1      Vote on Annual Report 2023, Consolidated Financial Statements 2023,
and Statutory Financial Statements 2023
1.2      Consultative vote on the Compensation Report 2023
1.3      Consultative vote on the Sustainability Report 2023
2.   Appropriation of available earnings
3.   Discharge of the Board of Directors and of the Executive Committee
4.   Amendments to the Articles of Association regarding share capital
4.1      Increase of conditional share capital
4.2      Deletion of Article 3C
5.   Board elections
5.1      (Re-)election of members of the Board of Directors
5.2      Election of the Chair of the Board of Directors
5.3      Re-election of members of the Nominating, Governance & Compensation Committee
6.   Vote on Board compensation and Executive Committee compensation
6.1      Approval of Board compensation (Non-Executive Directors) for the
2024-2025 term of office
6.2      Approval of Executive Committee compensation for 2025
7.   Re-election of the Independent Proxy
8.   Election of the statutory auditors

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America - the ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.


Anhang





Globe Newswire News

Zeit Meldung
08:00 GlobeNewswire: Tenneco stellt fortschrittliches hy
06:36 GlobeNewswire: Adalvo erhält erste Generika-Zulass
15.06. GlobeNewswire: Jinan Start-up Area: Sondierung hoc
14.06. GlobeNewswire: eGain im Gartner® Market Guide 2024
14.06. GlobeNewswire: GenTwo und issuance.swiss, unterstü
14.06. GlobeNewswire: Nikkiso Clean Energy & Industrial G
14.06. GlobeNewswire: Vertex erwirbt Steuerfähigkeiten im
13.06. GlobeNewswire: Lantronix gewinnt IoT Evolution Ass
13.06. GlobeNewswire: OBI Pharma gibt Beginn einer Phase-
13.06. GlobeNewswire: Chinesische Zhejiang-Universität se
12.06. GlobeNewswire: QIAGEN veröffentlicht Nachhaltigkei
12.06. GlobeNewswire: Rackspace Technology als führend im
12.06. GlobeNewswire: DeFi Technologies kündigt Einführun
12.06. GlobeNewswire: MY.GAMES stellt neues Publishing-La
12.06. GlobeNewswire: Lenkungs- und Fahrwerkssortiment vo
12.06. GlobeNewswire: SIKA ERÖFFNET NEUES HOCHMODERNES WE
12.06. GlobeNewswire: Aduro Clean Technologies erhöht Pri
11.06. GlobeNewswire: QIAGEN führt neue QIAcuity digitale
11.06. GlobeNewswire: Quantexa stellt die neue kontextori
10.06. GlobeNewswire: GKN Automotive hat 2023 direkte CO2
10.06. GlobeNewswire: Santhera gibt den Beginn eines Earl
10.06. GlobeNewswire: e& führt im Employer Brand Index 20
08.06. GlobeNewswire: Fahrerloser Minibus auf dem Sandpla
08.06. GlobeNewswire: Erste Kohorte von Absolventen einer
08.06. GlobeNewswire: Startschuss für Beijing Art Season:

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,